OS Therapies Inc

Listed Company

OSTXCIK 0001795091NYSEEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-28.80M

Total Assets

$6.84M

Equity

$-6.10M

Shares Out

39.53M

Op. Cash Flow

$-14.20M

Business

OS Therapies Inc is a clinical-stage biopharmaceutical company that identifies, develops and commercializes treatments for osteosarcoma and other solid tumors. It offers OST-HER2, an off-the-shelf Listeria-based immunotherapy expressing HER2 epitopes, and OST-tADC, a tunable antibody-drug conjugate platform with pH-sensitive silicon linkers and interchangeable payload cassettes. The company organizes its operations around product development programs, clinical trials (including human and veterinary indications), in-licensed intellectual property and collaborative research relationships. It conducts trials primarily in the United States, engages global CROs and contract manufacturers, and targets U.S. and other regulatory markets.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research and development	16	3	3
General and administrative	12	4	1
Loss from operations	−29	−7	−4
Interest income	249	—	2
Interest expense	—	−2	−3
Non-operating income	—	33,997	—
Non-operating expenses	−1	−51,250	—
Change in fair value of warrant liability	1	—	—
TOTAL OTHER INCOME/EXPENSE	−48,143	−2	−3
NET LOSS	−29	−9	−8
Cumulative Series A preferred stock dividend requirement	—	−31,250	—
NET LOSS available to common shareholders	−29	−9	−8
Weighted average # of shares (in Shares)	29	7	—
Basic loss per common share outstanding (in Dollars per share)	−0.98	−1.28	−1.46
Diluted loss per common share outstanding (in Dollars per share)	−0.98	−1.28	−1.46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash	269,830	6	38,982	—
Prepaid expenses	63,082	—	—	—
Total Current Assets	332,912	6	790,032	—
Fixed assets (net)	2,490	5,270	8,050	—
Patent (net of amortization)	7	—	—	—
Total-Long Term Assets	7	5,270	—	—
TOTAL ASSETS	7	6	798,082	—
Accounts payable	10	2	3	—
Accrued expenses	1	521,010	162,500	—
Accrued payroll and payroll taxes related party	36,792	97,257	112,137	—
Accrued payroll and payroll taxes	1,279	—	33,543	—
Preferred dividends payable	375,000	375,000	343,750	—
Warrant liability	—	2	—	—
Total Current Liabilities	12	5	25	—
TEDCO grant	100,000	100,000	100,000	—
Total Long-Term Liabilities	100,000	100,000	100,000	—
Total Liabilities	12	5	25	—
Commitments and contingencies (See Note 6)	—	—	—	—
Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively	1	4	—	—
Total Mezzanine Equity	1	4	—	—
Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively	37,116	20,870	5,340	—
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 0 and 0 shares outstanding, respectively	—	—	1,302	—
Additional paid-in capital	61	35	—	—
Accumulated deficit	−67	−38	−30	—
Total Stockholders Deficit	−6	−3	−24	−18
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS DEFICIT	7	6	798,082	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation and amortization expense	363,085	2,780	—
Amortization of debt discounts issuance and warrants	—	1	3
Shares issued for services	—	25,000	—
Shares issued for interest expense	—	8,523	—
Commitment shares issued for equity line of credit	568,235	—	—
Common shares issuance for services	595,841	—	—
Stock-based compensation	4	268,300	—
Amortization of non-cash prepaids	1	—	—
Accounts payable	8	−1	1
Accrued expenses	893,992	358,510	147,500
Accrued interest on convertible notes	—	613,605	802,479
Accrued Payroll and payroll taxes	−59,186	−48,423	—
Net cash used in operating activities	−14	−7	−3
Patent License Acquisition	−466,423	—	—
Net cash used in investing activities	−466,423	—	1,145
Prepaid warrants (net of fees)	530,162	—	—
Common stock issuance (net of fees)	8	—	—
Short-term borrowings	—	250,000	—
Short-term loan repayments	—	−250,000	—
Sale of preferred stock	1	6	—
Initial public offering (net of fees)	—	5	—
Net proceeds from conversion of debt A, B, C, D, E & F	—	2	3
Net cash provided by financing activities	9	13	3
Net change in cash	−5	5	−132,498
Cash paid for interest	—	—	—
Discount on notes payable redemption premium	—	750,500	2
Dividends payable	—	31,250	125,000
Deemed dividend on Series A convertible preferred stock	—	2	—
Mezzanine equity conversion (net of costs)	4	—	—
Conversion of preferred stock to common stock	—	1,302	—
Amortization of deferred offering costs	—	751,050	142,664
Conversion of convertible notes into common stock	—	25	—
Conversion of warrants into common stock	—	411	—
Issuance of common stock to investor advisor settlement	—	320	—
Conversion of make-whole liability to common stock	—	130,000	—
Clawback of common stock for over issuance	—	−670	—
Common stock issued for patent purchase	6	—	—
Reclassification of warrants liability to equity	878,153	—	—
Shares issued for prepaid services	1	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro